Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require?

Chris Henshall, Lloyd Sansom, Hans Georg Eichler, Alexandre Lemgruber, Carole Longson, Brian O'Rourke, Sean Tunis

Research output: Contribution to journalArticlepeer-review

Abstract

Pharmaceutical companies have a good understanding of the needs and requirements of regulatory bodies, but the evidence expectations of health technology assessment (HTA) and coverage/payer bodies are less well understood and addressed. This paper seeks to improve this understanding by providing an overview of the expectations of HTA and coverage/payer bodies, explaining how and why these differ from those of regulators, and describing the extent and limitations of work on harmonization. The article goes on to describe ways in which HTA and coverage/payer bodies' expectations can be addressed, and to encourage industry to interact with HTA and coverage/payer bodies to increase mutual understanding and hence promote more efficient development of and access to innovative medicines.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalTherapeutic Innovation and Regulatory Science
Volume48
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Clinical trials
  • Health technology assessment
  • Market access
  • Regulation
  • Reimbursement

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require?'. Together they form a unique fingerprint.

Cite this